Infliximab Therapy for Complicated Sarcoidosis
Authors: Matthew C. Cook
Journal: Annals of Internal Medicine (2002)

Letters20 August 2002Infliximab Therapy for Complicated SarcoidosisMatthew C. Cook, MD, PhD, FRACP, FRCPAMatthew C. Cook, MD, PhD, FRACP, FRCPAThe Canberra Hospital; 2606 Woden ACT, AustraliaAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-4-200208200-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Yee and Pochapin (1) report a case of sarcoidosis that is noteworthy not only for the dramatic response to infliximab but also for the unusual presentation. As discussed, this case represents empirical evidence of a novel therapy. The results from many pathophysiologic studies make this therapeutic response entirely plausible. Gene polymorphisms of tumor necrosis factor-α (TNF-α) that lead to elevated levels of circulating TNF-α have been found in patients with sarcoidosis, and TNF-α is expressed within sarcoid granulomas (2).Since the report describes such an unusual presentation for a case of sarcoidosis, it is worth reiterating that ...References1. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-α therapy. Ann Intern Med. 2001;135:27-31. [PMID: 11434729] LinkGoogle Scholar2. Seitzer U, Swider C, Stüber F, Suchnicki K, Lange A, Richter E, et al . Tumour necrosis factor α promoter gene polymorphism in sarcoidosis. Cytokine. 1997;9:787-90. [PMID: 9344512] CrossrefMedlineGoogle Scholar3. Amiri P, Locksley RM, Parslow TG, Sadick M, Rector E, Ritter D, et al . Tumour necrosis factor α restores granulomas and induces parasite egg-laying in schistosome-infected SCID mice. Nature. 1992;356:604-7. [PMID: 1560843] CrossrefMedlineGoogle Scholar4. Mechanic LJ, Dikman S, Cunningham-Rundles C. Granulomatous disease in common variable immunodeficiency. Ann Intern Med. 1997;127:613-7. [PMID: 9341059] LinkGoogle Scholar5. Smith KJ, Skelton H. Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor-α receptor fusion protein. Br J Dermatol. 2001;144:597-600. [PMID: 11260023] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: The Canberra Hospital; 2606 Woden ACT, Australia PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoTreatment of Complicated Sarcoidosis with Infliximab Anti–Tumor Necrosis Factor-α Therapy Arthur M.F. Yee and Mark B. Pochapin Infliximab Therapy for Complicated Sarcoidosis Terence M. O'Connor , Fergus Shanahan , and Charles P. Bredin Infliximab Therapy for Complicated Sarcoidosis Arthur M.F. Yee and Mark B. Pochapin Metrics Cited ByEfficacy and Safety of TNF Antagonists in Sarcoidosis: Data from the Spanish Registry of Biologics BIOBADASER and a Systematic ReviewInfliximab et sarcoïdose chronique. L'expérience française à propos de 31 casOcular Manifestations of SarcoidosisTreatment of refractory sarcoidal parotid gland swelling in a previously reported unresponsive caseAnti-TNF Biological Agents in Rheumatoid Arthritis and Other Inflammatory DiseasesA Review of the Use of Infliximab to Manage Cutaneous Dermatoses 20 August 2002Volume 137, Issue 4Page: 296KeywordsAutoimmunityGastrointestinal infectionsGranulomasHypergammaglobulinemiaImmunodeficienciesLymphocytesNecrosisSarcoidosis ePublished: 20 August 2002 Issue Published: 20 August 2002 CopyrightCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...